HAV Vaccines
"The Effect of Immunization with Inactivated Hepatitis A Vaccine on the Clinical Course of HIV-1 Infection: 1-Year Follow-Up."
Published in Vaccine Weekly, June 30th, 1997
According to the authors' abstract of an article published in AIDS, "Objective: To determine the long-term safety of inactivated hepatitis A virus (HAV) vaccine in men infected with HIV-1. Design: A 1-year prospective case-control study. Setting: Targeted primary care and sexually transmitted diseases clinics. Patients: Ninety HIV-1-positive patients who participated in an earlier efficacy study of HAV vaccination. Controls: Ninety HIV-1-positive men, matched for CD4+ lymphocyte percentage at baseline, who did not receive HAV vaccine. Intervention: All cases were assigned to receive two intramuscular doses of 1440...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
Source: Vaccine Weekly (1997-06-30)
More Articles from Vaccine Weekly
- AIDS Therapies
Immunotherapy Would Drive HIV Infected Cells to Suicide - AIDS Vaccines
Attenuated HIV Still Pathogenic in Mouse Model - AIDS Vaccines
Long-Term Protection of Chimps With Only Three Prime/Boost Immunizations - Animal Models
AIDS in Chimps May Lead to Direct Use of HIV in Monkeys - Herpes Vaccines
Replication-Deficient Herpes Simplex Induces Protective CTL - Industry News (Joint Venture)
ID Vaccine Acquires Rights to Vaccine Technology - More from this issue of Vaccine Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
